Placebo News and Research

RSS

Weight loss pill Lorcaserin found to have low cardiovascular risk

Weight loss pills have been discovered and then withdrawn from the market because of the risks that they pose to the heart. Some of them have raised the risk of heart attacks, suicides, heart valve problems significantly and have been thus banned.

27 Aug 2018

UAB receives NIH grant to continue evaluation of new medication for IPF

The University of Alabama at Birmingham has received a grant from the National Institutes of Health totaling $8.9 million to fund a multiyear program evaluating the role of a new medication in a clinical trial for patients suffering from idiopathic pulmonary fibrosis

24 Aug 2018

Researchers complete testing a new drug to treat rheumatoid arthritis

An international research group led by Charité - Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

23 Aug 2018

New research finds significant link between high Omega-3 Index and depression

New research published in the August edition of the Journal of the American College of Cardiology's Heart Failure issue found significant correlations between blood levels of EPA plus DHA omega-3s in "cognitive" depression among heart failure subjects.

22 Aug 2018

Research uncovers miscarriage cause, identifies potential targets for treatment

Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine. They identified a previously undiscovered gene mutation underlying hydrops fetalis – a fatal condition to fetuses due to fluid buildup in the space between organs.

16 Aug 2018

NIH begins first-in-human trial of experimental live, attenuated Zika virus vaccine

Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

16 Aug 2018

Powerful psychedelic compound can model near-death experiences in the brain

A powerful psychedelic compound found in ayahuasca can model near-death experiences in the brain, a study has found.

15 Aug 2018

Researchers discover new approach to alleviate chronic itch

Two receptors in the spinal cord and the right experimental drug: Researchers at the University of Zurich have discovered a new approach that suppresses itch.

14 Aug 2018

NIH grant for Mount Sinai to study use of inhaled corticosteroids for treatment of sickle cell disease

The Departments of Emergency Medicine and Hematology at the Icahn School of Medicine at Mount Sinai have been awarded a $4 million grant from the National Institutes of Health toward further study of inhaled corticosteroids to treat sickle cell disease in individuals who do not have asthma.

14 Aug 2018

FDA approves first oral medication for treatment of adults with Fabry disease

The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.

10 Aug 2018

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

10 Aug 2018

New study investigates whether nicotine could slow memory loss

Can nicotine slow or stop memory loss in people experiencing mild memory problems, or mild cognitive impairment? A new study being conducted at Georgetown University Medical Center aims to find out.

9 Aug 2018

Extended-release naltrexone appears to help HIV-positive patients reduce heavy drinking

Extended-release naltrexone -- an injection that decreases heavy drinking in the general population when taken in conjunction with counseling -- appears to help HIV-positive individuals reduce their number of heavy drinking days too, say Yale researchers.

7 Aug 2018

Otsuka’s JINARC approved for treatment of patients with CKD stage 4 ADPKD

Otsuka Pharmaceutical Europe Ltd. today announced that the European Commission has approved an extension of indication for JINARC to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease

2 Aug 2018

Peer comparison letters lead to persistent decrease in antipsychotic prescribing

A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel, an antipsychotic with potentially harmful side effects in the elderly, significantly reduced the number of prescriptions for patients in Medicare.

2 Aug 2018

Exenatide treatment improves depression symptoms in PD patients

Non-motor symptoms of Parkinson's disease, such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits.

1 Aug 2018

New method to evaluate drug benefits may reduce health care costs

With the cost of drugs a critical issue in health care, health insurance companies and government payers need to understand how new and existing drugs compare in terms of benefits and risks.

31 Jul 2018

New study provides insight into how stimulant treatments for ADHD work

Stimulant medications are an effective treatment for Attention-Deficit/Hyperactivity Disorder. In the classroom, parents and teachers say that medications like methylphenidate can reduce symptoms and improve behavior.

28 Jul 2018

Cannabis appears to have no effect on breathlessness during exercise in advanced COPD patients

Inhaled vaporized cannabis does not appear to improve or worsen exercise performance and activity-related breathlessness in patients with advanced chronic obstructive pulmonary disease, according to a randomized controlled trial published online in the Annals of the American Thoracic Society.

27 Jul 2018

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

27 Jul 2018